These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 954840)

  • 1. The interaction of delta9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm.
    Jones BC; Consroe PF; Laird HE
    Eur J Pharmacol; 1976 Aug; 38(2):253-9. PubMed ID: 954840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delta9-tetrahydrocannabinol methamphetamine interaction in the rabbit.
    Consroe PF; Jones BC; Akins F
    Neuropharmacology; 1975; 14(5-6):377-83. PubMed ID: 1171388
    [No Abstract]   [Full Text] [Related]  

  • 3. EEG and behavioral effects of delta9-tetrahydrocannabinol in combination with stimulant drugs in rabbits.
    Consroe P; Jones B; Laird H
    Psychopharmacology (Berl); 1976 Oct; 50(1):47-52. PubMed ID: 827761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance to delta9-tetrahydrocannabinol in adapted and nonadapted rabbits.
    Martin P; Consroe P
    Pharmacol Biochem Behav; 1978 Dec; 9(6):753-8. PubMed ID: 746051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic interaction between cannabinol and delta9-tetrahydrocannabinol.
    Takahashi RN; Karniol IG
    Psychopharmacologia; 1975; 41(3):277-84. PubMed ID: 168604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delta-9-tetrahydrocannabinol, EEG and behavior:the importance of adaptation to the testing milieu.
    Constoe PF; Jones BC; Chin L
    Pharmacol Biochem Behav; 1975; 3(2):173-7. PubMed ID: 1144477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of physostigmine and delta-9-tetrahydrocannabinol in man.
    Freemon FR; Rosenblatt JE; EL-Yousef MK
    Clin Pharmacol Ther; 1975 Feb; 17(2):121-6. PubMed ID: 1091392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects.
    Rupniak NM; Steventon MJ; Field MJ; Jennings CA; Iversen SD
    Psychopharmacology (Berl); 1989; 99(2):189-95. PubMed ID: 2508153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EEG spectral analysis for the evaluation of the central effects of delta6-tetrahydrocannabinol in rabbits.
    Willinsky MD; Loizzo A; Longo VG
    Psychopharmacologia; 1975; 41(2):123-6. PubMed ID: 1153604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of delta9-tetrahydrocannabinol and cannabinol in man.
    Karniol IG; Shirakawa I; Takahashi RN; Knobel E; Musty RE
    Pharmacology; 1975; 13(6):502-12. PubMed ID: 1221432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marihuana-like activity of new synthetic tetrahydrocannabinols.
    Martin BR; Dewey WL; Harris LS; Beckner J
    Pharmacol Biochem Behav; 1975; 3(5):849-53. PubMed ID: 1208625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide.
    Solinas M; Scherma M; Tanda G; Wertheim CE; Fratta W; Goldberg SR
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1127-34. PubMed ID: 17351107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats.
    Pryor GT; Larsen FF; Husain S; Braude MC
    Pharmacol Biochem Behav; 1978 Mar; 8(3):295-318. PubMed ID: 652837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress.
    Fokos S; Panagis G
    J Psychopharmacol; 2010 May; 24(5):767-77. PubMed ID: 19406854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinergic drugs and 4-aminopyridine alter hypoxic-induced behavioral deficits.
    Gibson GE; Pelmas CJ; Peterson C
    Pharmacol Biochem Behav; 1983 Jun; 18(6):909-16. PubMed ID: 6136988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epileptiform seizures in domestic fowl. V. The anticonvulsant activity of delta9-tetrahydrocannabinol.
    Johnson DD; McNeill JR; Crawford RD; Wilcox WC
    Can J Physiol Pharmacol; 1975 Dec; 53(6):1007-13. PubMed ID: 1222370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-delta9-tetrahydrocannabinol.
    Bhargava HN
    Eur J Pharmacol; 1976 Mar; 36(1):259-62. PubMed ID: 944134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
    Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delta9-tetrahydrocannabinol and aggressive behavior in rats.
    Miczek KA; Barry H
    Behav Biol; 1974 Jun; 11(2):261-7. PubMed ID: 4858807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.